Join the 'Carnexiv' group to help and get support from people like you.
Posted 5 Dec 2016 by Drugs.com
SUNDAY, Dec. 4, 2016 – People with epilepsy who experienced longer seizures during a simulated driving test may face an increased risk for crashes while on the road, a new study suggests. About 75 percent of people with epilepsy use medication to control their seizures and are able to drive. The remainder of patients typically keep a journal of seizures, noting how long they last, and doctors use that information to determine whether patients can drive safely, the study authors explained. The new study included 16 people with epilepsy who used a driving simulator for between one to 10 hours, most for an average of three to four hours. In total, the patients had 20 seizures, seven of which resulted in "crashes." The longer the seizure, the greater the chance of a "crash." Seizures lasted an average of 75 seconds among patients who crashed and 30 seconds among those who didn't crash. The ... Read more
Related support groups: Seizures, Topamax, Epilepsy, Keppra, Topiramate, Tegretol, Dilantin, Qsymia, Carbamazepine, Seizure Prevention, Levetiracetam, Phenytoin, Tegretol XR, Valproic Acid, Carbatrol, Epitol, Seizure Prophylaxis, Keppra XR, Phentermine/topiramate, Depakene
FDA Approves Carnexiv (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
Posted 10 Oct 2016 by Drugs.com
DEERFIELD, Ill.--(BUSINESS WIRE) October 07, 2016 --Lundbeck announced today that the U.S. Food and Drug Administration (FDA) has approved Carnexiv (carbamazepine) injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible. Carnexiv received orphan drug designation for this indication and will be the first available intravenous (IV) formulation of the antiepileptic drug (AED) carbamazepine. Lundbeck plans to make Carnexiv commercially available in the United States in early 2017. Carnexiv is a short-term (≤7 days) intravenous replacement therapy for oral carbamazepine formulations that provides continuity of care for adult patients who are unable to take carbamazepine by mouth and have the following seizure types: Partial seizures with complex symptomatology Generalized t ... Read more